Open AccessGenetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
Author(s) -
Bogota Francisco Jose RodríguezFundacion Oftalmologica Nacional,
Hernán Andrés Ríos,
María Camila Aguilar,
Shirley Rosenstiehl,
Nancy Gélvez,
Gina López,
Marta L. Tamayo
Publication year - 2019
Publication title -
taiwan journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.519
H-Index - 9
eISSN - 2211-5072
pISSN - 2211-5056
DOI - 10.4103/tjo.tjo_72_19
Subject(s) - macular degeneration , medicine , ranibizumab , ophthalmology , bevacizumab , chemotherapy
Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients over 55 years. Currently, the most common therapies for neovascular AMD (nAMD) are intravitreal antiangiogenics. Studies suggest that genetic factors influence on antiangiogenics therapy outcomes. The purpose of this work was to establish the association between complement factor H (CFH) (Y402H), age-related maculopathy susceptibility 2 (ARMS2) (A69S), and high-temperature requirement factor A1 (HTRA1) (rs11200638) polymorphisms and the response to treatment with ranibizumab in patients with nAMD.